Given the suggestion of differences in the association of 25(OH)D with prostate cancer by treatment arms among men with higher IGF analyte concentrations (Supplementary Tables S2 and S3), we tested whether treatment arm modified the association between 25(OH)D and prostate cancer among these men (Table 5). This evidence concerns the gene IGF1 and prostate carcinoma.